Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thalidomide and Hydroxyurea in Beta Thalassemia
NCT06490601Phase 2Active, not recruiting
- Sponsor
- National Institute of Blood and Marrow Transplant
- Start
- Apr 2022
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of thalidomide in beta thalassemia, sponsored by National Institute of Blood and Marrow Transplant. Started Apr 2022; status: active, not recruiting.
02
Drugs
thalidomide
03
Conditions
beta thalassemia
Beyond the preview
Go deeper on NCT06490601.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06490601.